Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 8236903, 8 pages
http://dx.doi.org/10.1155/2016/8236903
Research Article

Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study

1Division of Renal Medicine, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan
2Department of Internal Medicine, Taipei Medical University, Taipei, Taiwan
3Department of Rehabilitation, Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan
4Division of Biostatistics and Epidemiology, Department of Medical Research, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan

Received 27 May 2016; Accepted 11 August 2016

Academic Editor: John Maesaka

Copyright © 2016 Paik Seong Lim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Rajagopalan, S. Dellegrottaglie, A. L. Furniss et al., “Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Circulation, vol. 114, no. 18, pp. 1914–1922, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Guerrero, R. Montes, J. Muñoz-Terol et al., “Peripheral arterial disease in patients with stages IV and V chronic renal failure,” Nephrology Dialysis Transplantation, vol. 21, no. 12, pp. 3525–3531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. O'Hare, C.-Y. Hsu, P. Bacchetti, and K. L. Johansen, “Peripheral vascular disease risk factors among patients undergoing hemodialysis,” Journal of the American Society of Nephrology, vol. 13, no. 2, pp. 497–503, 2002. View at Google Scholar · View at Scopus
  4. S. G. De Vinuesa, M. Ortega, P. Martinez, M. Goicoechea, F. G. Campdera, and J. Luño, “Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors,” Kidney International, vol. 67, supplement 93, pp. S44–S47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Fishbane, S. Youn, E. Flaster, G. Adam, and J. K. Maesaka, “Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 27, no. 5, pp. 668–672, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Ono, A. Tsuchida, H. Kawai et al., “Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients,” Journal of the American Society of Nephrology, vol. 14, no. 6, pp. 1591–1598, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kitahara, K. Ono, A. Tsuchida et al., “Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 46, no. 4, pp. 688–696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Luo, X. Li, J. Li et al., “Peripheral arterial disease, chronic kidney disease, and mortality: the Chinese Ankle Brachial Index Cohort Study,” Vascular Medicine, vol. 15, no. 2, pp. 107–112, 2010. View at Publisher · View at Google Scholar
  9. A. O'Hare and K. Johansen, “Lower-extremity peripheral arterial disease among patients with end-stage renal disease,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2838–2847, 2001. View at Google Scholar · View at Scopus
  10. P. Alonso-Coello, S. Bellmunt, C. McGorrian et al., “Antithrombotic therapy in peripheral artery disease—antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, supplement, pp. e669S–e690S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. W. Rooke, A. T. Hirsch, S. Misra et al., “2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 58, no. 19, pp. 2020–2045, 2011. View at Publisher · View at Google Scholar
  12. C. Baigent, C. Sudlow, R. Collins, and R. Peto, “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. Palmer, L. Di Micco, M. Razavian et al., “Antiplatelet agents for chronic kidney disease,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD008834, 2013. View at Google Scholar · View at Scopus
  14. N. Jain, S. S. Hedayati, R. Sarode, S. Banerjee, and R. F. Reilly, “Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?” Clinical Journal of the American Society of Nephrology, vol. 8, no. 4, pp. 665–674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. E. Strandness Jr., R. L. Dalman, S. Panian et al., “Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study,” Vascular and Endovascular Surgery, vol. 36, no. 2, pp. 83–91, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Huang, Y. Cheng, J. Wu et al., “Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study,” The Lancet Neurology, vol. 7, no. 6, pp. 494–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Shinohara, Y. Katayama, S. Uchiyama et al., “Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial,” The Lancet Neurology, vol. 9, no. 10, pp. 959–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. K. Kamal, I. Naqvi, M. R. Husain, and B. A. Khealani, “Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD008076, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Uchiyama, B. M. Demaerschalk, S. Goto et al., “Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials,” Journal of Stroke and Cerebrovascular Diseases, vol. 18, no. 6, pp. 482–490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L.-G. Shi, J.-L. Pu, L. Xu, J. Malaguit, J. Zhang, and S. Chen, “The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population—an updated meta-analysis,” BMC Neurology, vol. 14, no. 1, article 251, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Qian and Q. Bi, “Systematic study of cilostazol on secondary stroke prevention: a meta-analysis,” European Journal of Medical Research, vol. 18, article 53, 2013. View at Publisher · View at Google Scholar
  22. C. J. Estol, P. M. Bath, P. B. Gorelick, D. Cotton, R. H. Martin, and PRoFESS Publications Committee and PRoFESS Investigators, “Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial,” International Journal of Stroke, vol. 9, supplement A100, pp. 43–47, 2014. View at Publisher · View at Google Scholar
  23. Y. Liu, Y. Shakur, M. Yoshitake, and J.-I. Kambayashi, “Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake,” Cardiovascular Drug Reviews, vol. 19, no. 4, pp. 369–386, 2001. View at Google Scholar · View at Scopus
  24. M. Matsumoto, “Cilostazol in secondary prevention of stroke: impact of the cilostazol stroke prevention study,” Atherosclerosis Supplements, vol. 6, no. 4, pp. 33–40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Tan, B. Margaret, J. H. Zhang et al., “Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis,” Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 5, pp. 930–938, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. Dinicolantonio, C. J. Lavie, H. Fares et al., “Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke,” American Journal of Cardiology, vol. 112, no. 8, pp. 1230–1234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Kambayashi, Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, and F. Czerwiec, “Cilostazol as a unique antithrombotic agent,” Current Pharmaceutical Design, vol. 9, no. 28, pp. 2289–2302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Suzuki, K. Uchida, N. Nakanishi, and Y. Hattori, “Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes,” American Journal of Hypertension, vol. 21, no. 4, pp. 451–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. C. J. Warner, S. W. Greaves, R. J. Larson et al., “Cilostazol is associated with improved outcomes after peripheral endovascular interventions,” Journal of Vascular Surgery, vol. 59, no. 6, pp. 1607–1614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Chen, Y. Zhang, Y. Tang, X. Huang, and Y. Xie, “Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons,” Current Medical Research and Opinion, vol. 30, no. 1, pp. 37–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Takagi and T. Umemoto, “Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials,” International Journal of Cardiology, vol. 153, no. 1, pp. 74–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Di Minno, A. Cerbone, M. Usberti et al., “Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen,” Journal of Laboratory and Clinical Medicine, vol. 108, no. 3, pp. 246–252, 1986. View at Google Scholar · View at Scopus
  33. J. W. Lohr and S. J. Schwab, “Minimizing hemorrhagic complications in dialysis patients,” Journal of the American Society of Nephrology, vol. 2, no. 5, pp. 961–975, 1991. View at Google Scholar · View at Scopus
  34. J. Éthier, J. L. Bragg-Gresham, L. Piera et al., “Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS),” American Journal of Kidney Diseases, vol. 50, no. 4, pp. 602–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Hiremath, R. M. Holden, D. Fergusson, and D. L. Zimmerman, “Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1347–1355, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Baigent, M. Landray, C. Leaper et al., “First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease,” American Journal of Kidney Diseases, vol. 45, no. 3, pp. 473–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. S. C. Palmer, L. D. Micco, M. Razavian et al., “Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 156, no. 6, pp. 445–459, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Kuwahara, S. Hasumi, S. Mandai et al., “Rate of ankle-brachial index decline predicts cardiovascular mortality in hemodialysis patients,” Therapeutic Apheresis and Dialysis, vol. 18, no. 1, pp. 9–18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Ogata, C. Kumata-Maeta, K. Shishido et al., “Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2199–2206, 2010. View at Publisher · View at Google Scholar · View at Scopus